The ASX200 has been up 0.5% at 8,582 points. The Aussie index pared early gains as speculation continues to swirl around the ...

Imugene's trial programs could result in the first 'off the shelf' Car-T therapy that uses healthy donors' cells.

Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to ...

Developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...

A solid end of session rally turned around a rather bleak start to the week, with the ASX 200 closing just 0.2% lower. Suncorp suffered the biggest meltdown despite its ex-dividend status being ...

What is ASX reporting season? Reporting or earnings season refers to the time of year when most publicly listed companies release their financial results to the market and announce the dividends ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Metrics Master Income Trust (MXT). However, you won't necessarily see their names in the ...

Welcome to my ChartWatch Daily ASX Scans series. Here I present scan lists based on my trend following technical analysis ...